Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Precision BioSciences (DTIL).
Precision BioSciences, Inc. recently announced the successful maturity of a $13 million convertible note, part of a strategic deal with Imugene Limited focusing on the cancer therapy azercabtagene zapreleucel. The company gained $9.75 million in cash and an additional $3.25 million in stock from Imugene, underscoring a significant financial milestone and a strengthened partnership in oncology.
For an in-depth examination of DTIL stock, go to TipRanks’ Stock Analysis page.